ArticleJournal of biological rhythms2017
Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma.
Article in Journal of biological rhythms, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Temozolomide Chronotherapy in Glioma: A Systematic Review.Current oncology (Toronto, Ont.) · 2023Pooled it
- Radiation chronotherapy-clinical impact of treatment time-of-day: a systematic review.Journal of neuro-oncology · 2019Pooled it
- Chronotherapy in Oncology: Aligning Cancer Treatment with Biological Time.Journal of personalized medicine · 2026Review
- Diurnal variation of cisplatin-induced anti-tumor effect and renal toxicity in mice bearing human colon cancer cells.Pharmacological reports : PR · 2026Article
- Nested ecosystems theory for conceptualizing brain tumors.Disease models & mechanisms · 2026Review
- Personalized chronotherapy in glioblastoma: integrating circadian profiling and PK-PD modelling to optimize temozolomide timing.NPJ precision oncology · 2025Article
- Targeting Cryptochromes in Chronic Diseases.Cell biology international · 2025Review
- Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma.Journal of neuro-oncology · 2025Article
- Circadian genesJournal of Zhejiang University. Science. B · 2025Review
- Circadian rhythms in pediatric high-grade gliomas may contribute to treatment efficacy.Scientific reports · 2025Article
- Circadian-Tuned Peptide Drug/Gene Co-Delivery Nanocomplexes to Enhance Glioblastoma Targeting and Transfection.International journal of molecular sciences · 2025Article
- The Circadian Rhythm Gene Network Could Distinguish Molecular Profile and Prognosis for Glioblastoma.International journal of molecular sciences · 2025Article
- Circadian rhythm related genes signature in glioma for drug resistance prediction: a comprehensive analysis integrating transcriptomics and machine learning.Discover oncology · 2025Article
- Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host.Cancer cell · 2025Article
- Unravelling the link between circadian clock genes and brain tumors: From pathological disruptions to potential therapeutic interventions.Frontiers in pharmacology · 2025Review
- Circadian rhythm disruption and endocrine-related tumors.World journal of clinical oncology · 2024Review
- Pharmacological Modulation of the Cytosolic Oscillator Affects Glioblastoma Cell Biology.Cellular and molecular neurobiology · 2024Article
- Enhancing structural diversity through chemical engineering of Ambrosia tenuifolia extract for novel anti-glioblastoma compounds.Scientific reports · 2024Article
- Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host.bioRxiv : the preprint server for biology · 2024Article
- Combined use of multiparametric high-content-screening and in vitro circadian reporter assays in neurotoxicity evaluation.Archives of toxicology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
Abstract
The safety and efficacy of chemotherapeutics can vary as a function of the time of their delivery during the day. This study aimed to improve the treatment of glioblastoma (GBM), the most common brain cancer, by testing whether the efficacy of the DNA alkylator temozolomide (TMZ) varies with the time of its administration. We found cell-intrinsic, daily rhythms in both human and mouse GBM cells. Circadian time of treatment affected TMZ sensitivity of murine GBM tumor cells in vitro. The maximum TMZ-induced DNA damage response, activation of apoptosis, and growth inhibition occurred near the daily peak in expression of the core clock gene Bmal1. Deletion of Bmal1 (Arntl) abolished circadian rhythms in gene expression and TMZ-induced activation of apoptosis and growth inhibition. These data indicate that tumor cell-intrinsic circadian rhythms are common to GBM tumors and can regulate TMZ cytotoxicity. Optimization of GBM treatment by timing TMZ administration to daily rhythms should be evaluated in prospective clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.